HIGHLANDS RANCH, Colo., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing ...

LITTLETON, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development ...

Vivos Therapeutics, Inc. has announced that its VidaSleep™ oral appliance, equipped with FDA-cleared Unilateral Bite Block technology, has received approval from the Centers for Medicare & Medicaid ...

Vivos Therapeutics, Inc. has announced the publication of positive results from a multicenter clinical trial on its Daytime-Nighttime Appliance (DNA) for treating obstructive sleep apnea (OSA) in ...

LITTLETON, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS) (“Vivos” or the “Company”), a pioneering medical technology company revolutionizing the treatment of obstructive ...

Symptoms of sleep-related breathing disorders decreased from 0.28 to 0.14, while snoring decreased by 58%. Vivos believes this breakthrough regulatory clearance represents a huge opportunity to ...

HIGHLANDS RANCH, Colo., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative ...

With over 80% of OSA cases in the United States undiagnosed and an estimated 80 million Americans affected, Vivos’ comprehensive portfolio of OSA treatments is poised to capture a significant share of ...

Important Milestone Clears the Way for Millions of Medicare Beneficiaries with Sleep Apnea to Access Vivos’ Patented and FDA-Cleared Oral Appliance Treatment LITTLETON, Colo., July 01, 2025 (GLOBE ...

(MENAFN- GlobeNewsWire - Nasdaq) Important Milestone Clears the Way for Millions of Medicare Beneficiaries with Sleep Apnea to Access Vivos' Patented and FDA-Cleared Oral Appliance Treatment With over ...